Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 660Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Xyzal

PharmaCompass

01

Brand Name : Xyzal

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Levocetirizine

Main Therapeutic Indication : Immunology

Currency : USD

2019 Revenue in Millions : 56

2018 Revenue in Millions : 45

Growth (%) : 24

Sanofi Company Banner

02

Brand Name : Xyzal

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Levocetirizine

Main Therapeutic Indication : Immunology

Currency : USD

2020 Revenue in Millions : -8

2019 Revenue in Millions : 62

Growth (%) : -114

Sanofi Company Banner

03

Brand Name : Xyzal

Levocetirizine

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Xyzal

arrow
Medlab Asia & Asia Health
Not Confirmed

Levocetirizine

Main Therapeutic Indication : Immunology

Currency : USD

2019 Revenue in Millions : 110

2018 Revenue in Millions : 98

Growth (%) : 12

blank

04

Brand Name : Xyzal

Levocetirizine

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Xyzal

arrow
Medlab Asia & Asia Health
Not Confirmed

Levocetirizine

Main Therapeutic Indication : Immunology

Currency : USD

2020 Revenue in Millions : 90

2019 Revenue in Millions : 122

Growth (%) : -27

blank

05

Brand Name : Xyzal

Levocetirizine

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Xyzal

arrow
Medlab Asia & Asia Health
Not Confirmed

Levocetirizine

Main Therapeutic Indication : Immunology

Currency : USD

2021 Revenue in Millions : 62

2020 Revenue in Millions : 90

Growth (%) : -24

blank

06

Brand Name : Xyzal

Levocetirizine

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Xyzal

arrow
Medlab Asia & Asia Health
Not Confirmed

Levocetirizine

Main Therapeutic Indication : Immunology

Currency : USD

2023 Revenue in Millions : 62

2022 Revenue in Millions : 61

Growth (%) : 0

blank

07

Brand Name : Xyzal

Levocetirizine Dihydrochloride

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Xyzal

arrow
Medlab Asia & Asia Health
Not Confirmed

Levocetirizine Dihydrochloride

Main Therapeutic Indication : Anti-Allergic

Currency : USD

2018 Revenue in Millions : 102

2017 Revenue in Millions : 118

Growth (%) : -13%

blank